Company Principia Biopharma Inc.

Principia Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies to patients with unmet medical needs in immunology and oncology. It uses its Tailored Covalency platform to design and develop reversible covalent and irreversible covalent, small molecule inhibitors. Its pipeline includes PRN1008, PRN1371 and PRN2246. PRN1008 drug candidate is designed for the treatment of chronic immunological disorders. PRN2246 is an irreversible covalent BTK inhibitor for the treatment of multiple sclerosis (MS), and other central nervous system (CNS) diseases. PRN1008 is also being developed for the treatment of multiple autoimmune diseases, such as pemphigus. PRN1371 is an inhibitor of Fibroblast Growth Factor Receptor (FGFR), designed for the treatment of solid tumors. The Company also focuses on developing oral immunoproteasome inhibitor for the treatment of inflammation and autoimmune disorders.